Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17619962 | 0.78 | PADI4 (0.38) | PTPN1NQO2 | |
| SCHEMBL22040413 | 0.71 | PTPN1 (0.47) | PTPN1KDM4EALDH1A1 | |
| SCHEMBL21546368 | 0.70 | PADI4 (0.36) | — | |
| SCHEMBL17620047 | 0.70 | KDM4E (0.39) | ITGB3ITGA2BKDM4E | |
| SCHEMBL17619954 | 0.70 | PADI4 (0.36) | — | |
| SCHEMBL22260620 | 0.69 | GRIN1 (0.35) | NQO2 | |
| SCHEMBL17620030 | 0.69 | GRIN1 (0.35) | NQO2 | |
| SCHEMBL21546358 | 0.68 | NPY4R (0.35) | PTPN1 | |
| SCHEMBL17619899 | 0.67 | WNT3A (0.38) | KDM4EALDH1A1 | |
| SCHEMBL20267071 | 0.66 | PTPN1 (0.51) | PTPN1NQO2KDM4ECHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340126-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340126-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | PTPN1 3550/4885NQO2 1039/4885ITGB3 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.